Cargando…

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate

In delayed-release dimethyl fumarate (DMF)-treated patients, absolute lymphocyte count (ALC) often declines in the first year and stabilizes thereafter; early declines have been associated with development of severe prolonged lymphopenia (SPL). Prolonged moderate or severe lymphopenia is a known ris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sangurdekar, Dipen, Sun, Chao, McLaughlin, Helen, Ayling-Rouse, Katherine, Allaire, Normand E., Penny, Michelle A., Bronson, Paola G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844186/ https://www.ncbi.nlm.nih.gov/pubmed/31749835 http://dx.doi.org/10.3389/fgene.2019.01039

Ejemplares similares

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance
por: Longbrake, Erin E, et al.
Publicado: (2015)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient
por: Kogel, Ann-Kathrin, et al.
Publicado: (2021)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies
por: Nakamura, Kunio, et al.
Publicado: (2022)

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
por: Ghadiri, Mahtab, et al.
Publicado: (2017)

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
por: Kowalec, Kaarina, et al.
Publicado: (2017)

Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age
por: Briner, Myriam, et al.
Publicado: (2019)

COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2020)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

COVID-19 in multiple sclerosis patients treated with dimethyl fumarate
por: Capone, Fioravante, et al.
Publicado: (2021)

Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate
por: Baharnoori, Moogeh, et al.
Publicado: (2016)

The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
por: Mills, Elizabeth A., et al.
Publicado: (2018)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions
por: Zinger, Nicole, et al.
Publicado: (2022)

No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis
por: Piervincenzi, Claudia, et al.
Publicado: (2022)

Effects Mediated by Dimethyl Fumarate on In Vitro Oligodendrocytes: Implications in Multiple Sclerosis
por: Guerriero, Claudia, et al.
Publicado: (2022)

Fumaric acid ester‐induced T‐cell lymphopenia in the real‐life treatment of psoriasis
por: Dickel, H., et al.
Publicado: (2019)

Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017)

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
por: Spencer, Collin M., et al.
Publicado: (2015)

Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate
por: Ma, Brandy B., et al.
Publicado: (2016)

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
por: Prosperini, Luca, et al.
Publicado: (2016)

Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models
por: Kihara, Yasuyuki, et al.
Publicado: (2015)

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2015)

The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
por: Hammer, Anna, et al.
Publicado: (2018)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

Lymphocyte subtypes in relapsing–remitting multiple sclerosis patients treated with dimethyl fumarate
por: Chaves, C, et al.
Publicado: (2017)

HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis
por: Blumenfeld Kan, S, et al.
Publicado: (2019)

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
por: Lyons, Jennifer, et al.
Publicado: (2022)

Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis
por: Ferri, Caterina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v0fk4aatuhulvn9dhportb6155